Vericel Corporation said the U.S. Food and Drug Administration approved commercial manufacturing of MACI (autologous cultured chondrocytes on porcine collagen membrane) at the company’s new cell therapy manufacturing facility in Burlington, Massachusetts. Vericel stated that the approval allows it to begin commercial production of MACI at the facility in the second quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vericel Corporation published the original content used to generate this news brief on March 04, 2026, and is solely responsible for the information contained therein.